Osimertinib - Wikipedia
Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7] [8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Osimertinib Uses, Side Effects & Warnings - Drugs.com
2024年5月30日 · What is osimertinib? Osimertinib is used to treat non-small cell lung cancer that is positive for an abnormal "EGFR" gene. You doctor will test you for this gene. Osimertinib is sometimes given when the cancer has spread to other parts of the body (metastatic), or may come back after surgery.
Osimertinib (oral route) - Mayo Clinic
2024年10月1日 · Osimertinib is used to treat non-small cell lung cancer (NSCLC) in patients who have certain types of abnormal epidermal growth factor (EGFR) genes. This medicine is used to prevent NSCLC from coming back in patients whose tumor has been removed by surgery.
Osimertinib (Tagrisso): Uses & Side Effects - Cleveland Clinic
OSIMERTINIB (OH sim ER ti nib) treats lung cancer. It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.
Tagrisso (osimertinib) - Uses, Side Effects, and More - WebMD
2024年6月25日 · Tagrisso (osimertinib) is commonly used for treating different kinds of epidermal growth factor receptor (EGFR) mutated lung cancer. EGFR is a protein on the surface of cells and...
Osimertinib (Tagrisso) | Cancer information - Cancer Research UK
2023年1月26日 · Osimertinib is a type of targeted cancer drug. It is a treatment for non small cell lung cancer (NSCLC). Find out about how you have it, possible side effects and other important information.
Tagrisso: Uses, Dosage, Side Effects & Warnings - Drugs.com
2024年9月30日 · Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have certain abnormal epidermal growth factor receptor (EGFR) gene(s) and who fit certain other criteria.
Osimertinib Mesylate - NCI - National Cancer Institute
Osimertinib mesylate is approved to treat: Non-small cell lung cancer that has an abnormal EGFR gene. It is used in adults: who have had surgery to remove the cancer, to help keep the cancer from coming back after surgery
Osimertinib: MedlinePlus Drug Information
Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors.
Osimertinib: Uses, Interactions, Mechanism of Action - DrugBank …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. 1,9 Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA ...